Diversified by geography and business mix, Fresenius should be able to benefit from ongoing growth in treating ESRD patients worldwide in the long run.
1 Day FME 7.69% DJIA 0.37% Russell 2K -0.38% Basic Materials/Resources 0.25% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback